Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25695775 | 0.78 | LMNA (0.44) | TYRLMNACYP2C9TRPA1PTGS1 | |
| SCHEMBL20852892 | 0.77 | CYP3A4 (0.41) | LMNAALDH1A1GAAALOX12HTT | |
| SCHEMBL18489056 | 0.73 | MAPT (0.39) | ALDH1A1GAA | |
| SCHEMBL24023641 | 0.72 | CYP2C9 (0.37) | LMNACYP2C9ALDH1A1GAA | |
| SCHEMBL30322428 | 0.71 | LMNA (0.52) | TYRLMNATRPA1PTGS1CACNA1C | |
| SCHEMBL7122025 | 0.71 | LMNA (0.52) | TYRLMNATRPA1PTGS1CACNA1C | |
| SCHEMBL449241 | 0.71 | TYR (0.40) | TYRLMNATRPA1PTGS1CACNA1C | |
| SCHEMBL25599236 | 0.70 | TYR (0.38) | TYRLMNACYP2C9TRPA1PTGS1 | |
| SCHEMBL24173430 | 0.69 | ALDH1A1 (0.43) | TYRLMNACYP2C9TRPA1PTGS1 | |
| SCHEMBL22422813 | 0.69 | ALDH1A1 (0.47) | TYRLMNATRPA1PTGS1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355103-A1 | PARG INHIBITORS AND METHOD OF USE THEREOF | CITY OF HOPE | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355103-A1 | PARG INHIBITORS AND METHOD OF USE THEREOF | PARG, PARP12, PARN | TYR 1440/4885LMNA 883/4885CYP2C9 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.